Economic modeling reveals how international health funding cuts could devastate tuberculosis patients across 79 low- and middle-income countries, shifting massive treatment costs from governments to vulnerable households already struggling with poverty and disease. The analysis examined six funding reduction scenarios spanning 2025-2050, with researchers quantifying both total patient-incurred expenses and households pushed into catastrophic spending territory. Terminating USAID alone would generate $7.5 billion in additional out-of-pocket costs for TB patients, while forcing 3.9 million households to spend more than 20% of their annual income on disease-related expenses. Complete elimination of external TB funding produced the most severe projections: $79.7 billion in shifted costs and widespread household financial ruin. The modeling incorporates both epidemiological dynamics and economic realities, tracking how reduced international support translates into higher patient co-pays, longer treatment delays, and increased indirect costs from lost productivity. This represents a fundamental shift in global health burden distribution, moving costs from wealthy donor nations to the world's most economically vulnerable populations. The findings illuminate a critical policy paradox in global health financing: while international funding aims to reduce disease burden in developing nations, its withdrawal doesn't eliminate costs but rather transfers them to those least equipped to bear them. For health-conscious adults in donor countries, this analysis underscores how international health investments function as both humanitarian aid and practical disease containment strategies that ultimately benefit global health security.